A 50-year-old man with CKD stage 4 (GFR 22 mL/min) due to diabetic nephropathy has serum potassium of 5.8 mEq/L on ACE inhibitor. He has hyperphosphataemia (2.1 mmol/L), elevated intact PTH (350 pg/mL), and hypocalcaemia (2.0 mmol/L). Which intervention is most critical to prevent progression to tertiary hyperparathyroidism and metastatic calcification?
- A Non-calcium-based phosphate binders (sevelamer/lanthanum) to control phosphate without calcium loading ✓
- B Calcium carbonate as phosphate binder with each meal
- C Active vitamin D (calcitriol) supplementation to raise serum calcium
- D Cinacalcet (calcimimetic) to suppress PTH directly
Explanation
In advanced CKD with hyperphosphataemia, controlling hyperphosphataemia is the priority in secondary hyperparathyroidism management. Non-calcium-based phosphate binders (sevelamer carbonate or lanthanum carbonate) are preferred over calcium carbonate, because calcium loading in CKD with vascular calcification increases cardiovascular mortality. The ADVANCE trial showed sevelamer significantly reduced progression of coronary artery calcification compared to calcium-based binders. Active vitamin D (calcitriol/paricalcitol) is added after phosphate is controlled to prevent adynamic bone disease and suppress PTH, but not before, as it may worsen hypercalcaemia and phosphate absorption. Cinacalcet is used for dialysis patients, not pre-dialysis CKD.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.